M&As this week: Kuros Biosciences, Allergan, Agilent Technologies


Kuros Biosciences intends to acquire Xpand Biotechnology by way of an exchange of all Xpand shares for up to 2.105m of new Kuros shares.

The acquisition will enable Kuros, a tissue repair and regeneration products developer, to accelerate its transition into a commercial-stage developer with two products ready for commercialisation in the EU by 2017, one of which is also expected to obtain approval in the US.

It also provides the company access to Xpand’s GMP-controlled manufacturing capabilities in the Netherlands.

"The acquisition will enable Kuros, a tissue repair and regeneration products developer, to accelerate its transition into a commercial-stage developer."

In a move to enter the regenerative medicine segment, Allergan Holdco US, a subsidiary of Allergan, has signed a definitive agreement to acquire LifeCell Corporation from Acelity, for a cash consideration of $2.9bn.

The acquisition will add LifeCell’s novel, regenerative medicines business including its portfolio of dermal matrix products to Allergan's existing portfolio of medical aesthetics, breast implants and tissue expanders and enables it to develop and commercialise wound therapies and dressings in markets across the globe.

The transaction will also provide Allergan access to LifeCell’s innovative manufacturing capabilities and its research and development (R&D) operations in the US.

Agilent Technologies intends to purchase Multiplicom, a molecular diagnostic solution provider, for a cash consideration of approximately $71m.

The transaction, which will be completed before January 2017, will enable Agilent to strengthen its presence in the genomics market and to expand its target-enrichment portfolio.

Molecular diagnostics company Premaitha Health intends to acquire bioinformatics solutions provider Yourgene Bioscience for $8.97m to be paid in cash and stock.

The acquisition, which will be completed on 31 January 2017, will enable the acquirer to expand its market access in Asia and gain from cross-selling opportunities and strategic drive into China.

Ningbo Medical System Biotechnology, an in-vitro diagnostic products provider, intends to sell 51% stake for $6.47m.

Drug delivery systems developer PixarBiointends intends to acquire InVivo Therapeutics Holdings for $77m in stock.

Following the acquisition, which will be completed in March 2017, the company will be renamed as Reynolds Therapeutics and will focus on the development of post-surgical pain treatments and other neurological treatments.

As a part of its growth strategy to invest in key innovative platforms, DePuy Synthes, a Johnson & Johnson company offering medical devices and solutions in orthopaedics, spinal care and neurosciencs, has agreed to purchase expandable cage and minimally invasive surgery (MIS) technologies for spinal fusion, from its developer Interventional Spine.

The company also has plans to acquire Interventional Spine's facet screw system for open and percutaneous spine surgery.